Pipeline and assets for immunotherapy programs
Our partnered programs, internal pipeline, and asset library for developers of biologics, vaccines, and T-cell therapeutics.
Neoantigen and shared antigen immunotherapeutics
We are instrumental in the (co-)development of both off-the-shelf and personalized therapeutics using our state-of-the-art ImmunoEngine platform. We have multiple partnered programs ongoing, of which 1 off-the-shelf and 1 personalized cancer vaccine trial have received IND/CTA approval with recruitment underway, and 1 personalized trial is ongoing.
| Partner | Disease | Therapy | Pre-clinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|
| CureVac (BioNTech) | NSCLC | Off-the-shelf mRNA | |||
| CureVac (BioNTech) | Undisclosed | Off-the-shelf mRNA | |||
| University of Liverpool | NSCLC | Personalized DNA | |||
| Undisclosed EU partner | Solid tumors | Personalized DNA | |||
| Undisclosed US partner | Solid tumors | Personalized MVA | |||
Camyotope-targeted and personalized immunotherapeutics
We are advancing our first internal program MNE-C261 in microsatellite-stable colorectal cancer (MSS-CRC) to the clinic with the aim of initiating the clinical phase by Q4 2027.
| Program | Disease | Therapy | Target | Pre-clinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|---|
| MNE-C261 | MSS-CRC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX2 | TNBC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX3 | PAAD | Off-the-shelf mRNA | Camyotopes | |||
| MNE-P201 | Solid tumors | Personalized mRNA | Neoantigens | |||
MNE-C261: mRNA-LNP vaccine
- 26 CRC-specific camyotope targets
- Strong polyfunctional immunogenicity
- Very high target abundance: up to 99%
- Exceptional coverage: more than 95%
- Broad HLA-coverage: more than 95%
Multiple other off-the-shelf programs, as well as a personalized program, are in late discovery / early pre-clinical phase.
Unique assets for biologics, vaccine, and T-cell therapeutics developers
We have a broad asset portfolio of MHC-bound and surface antigen targets in a multitude of cancer indications. The targets have been selected and prioritized through our proprietary computational discovery workflows. Explore our solutions and publications to see how these targets can be leveraged for your development programs.
Colorectal cancer
Bladder cancer
Breast cancer
Glioblastoma
Pancreatic cancer
Liver cancer
Cervical cancer
Head and neck cancer
What is the myNEO antigen target library?
The myNEO antigen target library contains MHC-bound and surface antigen targets identified and prioritized across a range of cancer indications. These targets are available for licensing to biologics, vaccine, and T-cell therapy developers.
Which cancer indications does myNEO's target discovery cover?
myNEO's target discovery currently covers colorectal, bladder, breast, pancreatic, liver, cervical, and head and neck cancers, as well as glioblastoma.
What internal programs is myNEO developing?
As of August 2026, myNEO's lead program is MNE-C261, an off-the-shelf mRNA vaccine targeting camyotopes in microsatellite-stable colorectal cancer. The program is in preclinical development, with clinical initiation targeted for Q4 2027. The pipeline also lists MNE-CXX2, MNE-CXX3, and the personalized MNE-P201 program.
What partnered programs use myNEO's technology?
myNEO's technology is used in a Phase I personalized DNA program with the University of Liverpool for patients with non-small cell lung cancer. Two additional personalized programs are at the preclinical stage with undisclosed European and US partners targeting solid tumors.
What partnership opportunities does myNEO offer?
myNEO discusses target licensing, strategic collaborations, co-development, and use of its technologies within partner programs. Commercial structures, exclusivity, territory, and access models are agreed for each opportunity.
Talk to our team
Discuss partnered programs, internal assets, or licensing from the antigen target library.